The two most common KRAS mutations in NSCLC are G12C (~ 40%) and G12V (~ 22%), leading to an impairment of KRAS intrinsic hydrolytic activity and increased activation of KRAS oncoprotein3. This evidence concerns the gene KRAS and non-small cell lung carcinoma.